Cargando…
Immunohistochemical analysis of organic anion transporter 2 and reduced folate carrier 1 in colorectal cancer: Significance as a predictor of response to oral uracil/ftorafur plus leucovorin chemotherapy
Colorectal cancer is one of the most common malignancies in developed countries and chemotherapy is the standard treatment option for advanced colorectal cancer. Identification of biomarkers for predicting response to uracil/ftorafur plus leucovorin (UFT/LV) chemotherapy is an important issue in col...
Autores principales: | NISHINO, SATOSHI, ITOH, AYUMI, MATSUOKA, HIROSHI, MAEDA, KOTARO, KAMOSHIDA, SHINGO |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3916200/ https://www.ncbi.nlm.nih.gov/pubmed/24649225 http://dx.doi.org/10.3892/mco.2013.104 |
Ejemplares similares
-
‘A phase II study of oral uracil/ftorafur (UFT®) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer’
por: Bennouna, J, et al.
Publicado: (2006) -
Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study
por: Bajetta, E, et al.
Publicado: (2007) -
Complete Response of Pulmonary Metastases from Rectal Cancer to Tegafur-Uracil/Leucovorin plus Bevacizumab in an Elderly Patient: A Case Report
por: Shibutani, Masatsune, et al.
Publicado: (2018) -
Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer
por: Cellier, Patrice, et al.
Publicado: (2011) -
A phase II study of preoperative chemoradiation with tegafur-uracil plus leucovorin for locally advanced rectal cancer with pharmacogenetic analysis
por: Kim, Sun Young, et al.
Publicado: (2017)